Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
暂无分享,去创建一个
M. Dowsett | S. Johnston | I. Smith | S. Pancholi | S. Detre | J. Head | L. Martin
[1] V. Keshamouni,et al. Mechanism of 17-β-Estradiol-induced Erk1/2 Activation in Breast Cancer Cells , 2002, The Journal of Biological Chemistry.
[2] J. Schellens,et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Kris,et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Bianco,et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. , 2001, Cancer research.
[5] M. Dowsett,et al. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] N. Rosen,et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. , 2001, Cancer research.
[7] N. Hynes,et al. Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents , 2001, Oncogene.
[8] G. Bollag,et al. Discovery of a novel Raf kinase inhibitor. , 2001, Endocrine-related cancer.
[9] Monilola A. Olayioye,et al. The ErbB receptor tyrosine family as signal integrators. , 2001, Endocrine-related cancer.
[10] P. Frost,et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. , 2001, Endocrine-related cancer.
[11] I. Ellis,et al. Phosphorylation of ERK1/2 mitogen‐activated protein kinase is associated with poor response to anti‐hormonal therapy and decreased patient survival in clinical breast cancer , 2001, International journal of cancer.
[12] R. Nicholson,et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). , 2001, Endocrinology.
[13] E K Rowinsky,et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Nicholson,et al. The EGFR-selective tyrosine kinase inhibitor ZD1839 (‘Iressa’) is an effective inhibitor of tamoxifen-resistant breast cancer growth , 2001 .
[15] R. Schiff,et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. , 2000, Journal of the National Cancer Institute.
[16] A. Lenferink,et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. , 2000, Cancer research.
[17] G. Hurst,et al. The lateral arm for stereotactic biopsy: how good is it? , 2000, Breast Cancer Research.
[18] K. Ley,et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase , 2000, Nature.
[19] Ji-ping Wang,et al. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells , 2000, Breast Cancer Research and Treatment.
[20] S. Hilsenbeck,et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. , 2000, Cancer research.
[21] J. Font de Mora,et al. AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor , 2000, Molecular and Cellular Biology.
[22] G. Tortora,et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] W. R. Bishop,et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. , 2000, Cancer research.
[24] M. Dowsett,et al. The involvement of the MAPK signalling pathway in the adaptation of MCF-7 cells to long-term oestrogen deprivation , 2000, Breast Cancer Research.
[25] E. Sausville,et al. Preclinical and clinical development of cyclin-dependent kinase modulators. , 2000, Journal of the National Cancer Institute.
[26] D. W. Fry,et al. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. , 2000, Anti-cancer drug design.
[27] L. Moore,et al. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. , 1999, Cancer research.
[28] G. Prendergast,et al. Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. , 1999, Cancer research.
[29] J. Robertson,et al. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. , 1999, Endocrine-related cancer.
[30] S. Hilsenbeck,et al. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. , 1999, Molecular endocrinology.
[31] I. Ellis,et al. Endocrine response and resistance in breast cancer: a role for the transcription factor Fos , 1999, International journal of cancer.
[32] M. Dowsett,et al. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] Walter A. Korfmacher,et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. , 1998, Cancer research.
[34] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[35] C. Osborne,et al. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. , 1997, Cancer research.
[36] D. Picard,et al. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.
[37] C. Der,et al. Aberrant function of the Ras signal transduction pathway in human breast cancer , 1995, Breast Cancer Research and Treatment.
[38] A. Mahfoudi,et al. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[39] P. Webb,et al. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. , 1995, Molecular endocrinology.
[40] G. T. Budd,et al. Estrogen receptor mutations in tamoxifen-resistant breast cancer. , 1994, Cancer research.
[41] J. Cairns,et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. , 1992, British Journal of Cancer.
[42] R. Nicholson,et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. , 2002, Cancer research.
[43] C. Bowden,et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. , 2001, Cancer research.
[44] S. Johnston,et al. Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer. , 2001, The Lancet. Oncology.
[45] M. Piccart-Gebhart,et al. A clinical, pharmacokinetic and pharmacodynamic phase I study of the raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors , 2001 .